Back to Search
Start Over
Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study
- Source :
- The Lancet; August 2024, Vol. 404 Issue: 10452 p540-553, 14p
- Publication Year :
- 2024
-
Abstract
- Sjögren's disease is a chronic autoimmune disease with an unmet need for targeted therapies. The aim of the TWINSS study is to evaluate the safety and efficacy of iscalimab, a monoclonal antibody against CD40, in patients with active Sjögren's disease.
Details
- Language :
- English
- ISSN :
- 01406736 and 1474547X
- Volume :
- 404
- Issue :
- 10452
- Database :
- Supplemental Index
- Journal :
- The Lancet
- Publication Type :
- Periodical
- Accession number :
- ejs67108503
- Full Text :
- https://doi.org/10.1016/S0140-6736(24)01211-X